Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AKTX | 8-K | bearish | 7/10 | Akari Therapeutics entered into a securities purchase agreement to raise approximately $5.5 million in gross proceeds th | May 22, 2026 |
| AKAN | 6-K | bearish | 7/10 | Akanda Corp. received a Nasdaq deficiency notice for failing to file its FY2025 20-F by the due date, triggering a non-c | May 22, 2026 |
| GLSI | PRESS-RELEASE | bearish | 6/10 | Greenwich LifeSciences reported Q3 2025 EPS of -$0.30, beating consensus of -$0.32 by 6.3%, but the press release primar | May 22, 2026 |
| TOIIW | 8-K | bearish | 5/10 | Oncology Institute discloses that its third-party software vendor notified the company on May 20, 2026 that patient data | May 22, 2026 |
| PHAR | 6-K | bullish | 7/10 | Pharming announces that the European Commission has granted marketing authorization for Joenja (leniolisib) as the first | May 22, 2026 |
| MRK | 8-K | neutral | 3/10 | Merck issued $4.0 billion in aggregate principal amount of new senior unsecured notes across six tranches on May 22, 202 | May 22, 2026 |
| SCYX | 8-K | neutral | 4/10 | SCYNEXIS shareholders approved a reverse stock split at a special meeting on May 19, 2026, with 44.8M votes for and 6.7M | May 22, 2026 |
| NBTX | PRESS-RELEASE | mixed | 6/10 | Nanobiotix closed its $100M global offering after underwriters fully exercised their option for 33,805 additional ADSs a | May 22, 2026 |
| ARDX | CLUSTER | neutral | 2/10 | Seven ARDX insiders, including CEO and CFO, sold a combined $176K in shares on May 21, 2026, all at the same price of $6 | May 22, 2026 |
| NRXPW | 25-NSE | bearish | 8/10 | Nasdaq filed a Form 25-NSE to remove from listing and deregister the warrants (NRXPW) of NRX Pharmaceuticals, Inc., effe | May 22, 2026 |
| AAVXF | 6-K | neutral | 5/10 | Abivax reported Q1 2026 financial results with a net loss of €48.5 million, improved from a €52.4 million loss in Q1 202 | May 22, 2026 |
| ARDX | CLUSTER | neutral | 3/10 | Four C-suite insiders at Ardelyx sold $141K in open-market sales on the same day (May 21, 2026), including the CEO dispo | May 22, 2026 |
| XTLB | 6-K | bearish | 8/10 | XTL Biopharmaceuticals received a Staff delist determination from Nasdaq on May 18, 2026, due to failure to file its Ann | May 22, 2026 |
| ABVX | PRESS-RELEASE | neutral | 5/10 | Abivax reported Q1 2026 net loss of €48.5M (vs €52.4M loss in Q1 2025) with operating loss of €56.2M. The press release | May 22, 2026 |
| IVEVF | 6-K | bearish | 6/10 | Inventiva filed its notice of meeting for the Ordinary and Extraordinary General Meeting scheduled June 30, 2026. Key it | May 22, 2026 |
| FENC | 8-K | neutral | 4/10 | Fennec Pharmaceuticals announced that four independently led studies on PEDMARK (sodium thiosulfate injection) will be p | May 22, 2026 |
| KURA | CLUSTER | neutral | 2/10 | Three KURA C-suite insiders (COO, CLO, CCO) sold a total of $152K in open-market sales over a 7-day window, occurring 10 | May 22, 2026 |
| SNSE | DEFA14A | neutral | 3/10 | Sensei Biotherapeutics filed a DEFA14A supplement to its definitive proxy statement, updating board reconstitution plans | May 22, 2026 |
| CRIS | 8-K | bearish | 6/10 | Curis Inc. shareholders approved a charter amendment at the May 19, 2026 annual meeting to nearly double authorized comm | May 22, 2026 |
| SNSE | 8-K | neutral | 2/10 | Sensei Biotherapeutics filed an 8-K disclosing that director nominee Karen Vousden requested a delay in her board appoin | May 22, 2026 |
| ASMB | 424B5 | bearish | 6/10 | Assembly Biosciences (ASMB) filed a preliminary prospectus supplement for an underwritten public offering of common stoc | May 22, 2026 |
| SER | S-3 | bearish | 7/10 | Serina Therapeutics filed an S-3 registration statement to register up to 16,450,442 shares of common stock for resale b | May 22, 2026 |
| MBRX | 8-K | neutral | 4/10 | Moleculin announced that an abstract on pooled cardiac safety data for Annamycin has been accepted for a poster presenta | May 22, 2026 |
| PHVS | CLUSTER | neutral | 3/10 | Five Pharvaris insiders, including the CEO and CCO, sold a total of ~$1.08M in open-market sales over a 7-day window, fo | May 22, 2026 |
| PTHS | 144 | neutral | 2/10 | Francis Knuettel II, an officer of Pelthos Therapeutics Inc. (PTHS), filed a Form 144 on 5/22/2026 indicating intent to | May 22, 2026 |
| QUCY | 144 | neutral | 3/10 | Director Guido Baechler filed a Form 144 to sell 240,000 shares of Quantum Cyber (QUCY), valued at approximately $904,80 | May 22, 2026 |
| RGC | 6-K | bearish | 6/10 | Regencell Bioscience announced the closing of a ~$20M registered direct offering of 985,222 shares at $20.30 each, a 27% | May 22, 2026 |
| MEHA | 8-K | bearish | 7/10 | Functional Brands Inc. (MEHA) entered into a definitive Asset Purchase Agreement to acquire the Alchemy gold-backed bloc | May 22, 2026 |
| ONCY | 8-K | neutral | 3/10 | Oncolytics announced translational data from the GOBLET and AWARE-1 trials to be presented at ASCO 2026, showing pelareo | May 22, 2026 |
| ONCY | PRESS-RELEASE | neutral | 4/10 | Oncolytics Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at ASCO 2026, showi | May 22, 2026 |